Enforcement and litigation
If a company hasn't received an FDA warning letter, does that mean its products are compliant?
Plain English first, then the primary source. Education, not legal advice.
Interpretation
In short: enforcement discretion is not permission, and it can change without notice.
Plain English
A warning letter is a notice FDA sends when it believes it has identified significant violations, and it is often a step FDA takes before considering more formal action, though FDA can also pursue other actions without first issuing a warning letter. FDA itself has explained that matters described in a warning letter may change after the letter is issued, and closure of a warning letter does not certify products or practices as compliant going forward.
FDA has limited resources and exercises enforcement discretion, meaning it does not pursue every possible violation. The absence of enforcement action against a particular company is not evidence that its practices are lawful, only that FDA has not yet acted or has chosen not to.
Warning letters are a useful signal of what FDA considers a violation in similar circumstances, and reviewing them is a common way to learn how the agency applies its rules in practice.
Why it matters
- This corrects the common but incorrect inference that a competitor's lack of enforcement history is proof of legality.
Where the answer becomes fact-specific
The Foundation does not manufacture legal conclusions. These points change the analysis and may require qualified regulatory counsel.
- Enforcement patterns can shift with agency priorities, so historical enforcement gaps are not a reliable predictor of future action.